PKC delta and epsilon in drug targeting and therapeutics

Recent Patents on DNA and Gene Sequences

Volumn 3, Issue 2, 2009, Pages 96-101

  Yonezawa, Tomo ^a   Kurata, Riho ^a   Kimura, Minoru ^a   Inoko, Hidetoshi ^a  

^a TOKAI UNIVERSITY   (Japan)

Author keywords

KAI 1678; KAI 9803; KCe 12; KCe 16; Protein kinase C (PKC); Selective peptide modulator

Indexed keywords

ALDEHYDE DEHYDROGENASE ISOENZYME 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KAI 1678; KAI 9803; KCE 12 PEPTIDE; KCE 16 PEPTIDE; PROTEIN KINASE C; PROTEIN KINASE C BETA; PROTEIN KINASE C DELTA; PROTEIN KINASE C EPSILON; PROTEIN KINASE C GAMMA; PROTEIN KINASE C INHIBITOR; PROTEIN KINASE C LAMBDA; PROTEIN KINASE C ZETA; RECEPTOR FOR ACTIVATED C KINASE 1; RECEPTOR FOR ACTIVATED C KINASE 2; UNCLASSIFIED DRUG; ENZYME INHIBITOR; PEPTIDE;

ACUTE HEART INFARCTION; ANTINOCICEPTION; BINDING SITE; BIOTECHNOLOGY; COMPETITIVE INHIBITION; DIABETES MELLITUS; DRUG TARGETING; ENZYME SUBSTRATE COMPLEX; GENE TARGETING; HIPPOCAMPUS; HUMAN; ISCHEMIC HEART DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUTRITIONAL DIABETES; PATENT; POSTOPERATIVE PAIN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; REVIEW; SEQUENCE HOMOLOGY; T LYMPHOCYTE ACTIVATION; ANIMAL; DRUG ANTAGONISM; GENETICS; METABOLISM;

RODENTIA;

ANIMALS; ENZYME INHIBITORS; GENE TARGETING; HUMANS; PATENTS AS TOPIC; PEPTIDES; PROTEIN KINASE C-DELTA; PROTEIN KINASE C-EPSILON;

EID: 70349254473     PISSN: 18722156     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221509788654205     Document Type: Review

References (75)

1. Takai Y, Kishimoto A, Inoue M, Nishizuka Y. Studies on a cyclic nucleotide-independent protein kinase and its proenzyme in mammalian tissues. I. Purification and characterization of an active enzyme from bovine cerebellum. J Biol Chem 1977; 252: 7603-7609.
2. Nishizuka Y. The role of protein kinase C in cell surface signal transduction and tumour promotion. Nature 1984; 308: 693-698. (Pubitemid 14127666)
3. Dekker LV, Parker PJ. Protein kinase C-a question of specificity. Trends Biochem Sci 1994; 19: 73-77. (Pubitemid 24055564)
4. Steinberg SF. Structural basis of protein kinase C isoform function. Physiol Rev 2008; 88: 1341-1378.
5. Griner EM, Kazanietz MG. Protein kinase C and other diacylglycerol effectors in cancer. Nat Rev Cancer 2007; 7: 281-294. (Pubitemid 46480971)
6. Khasar SG, Lin YH, Martin A, et al. A novel nociceptor signaling pathway revealed in protein kinase C epsilon mutant mice. Neuron 1999; 24: 253-260. (Pubitemid 29466163)
7. Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes 1998; 47: 859-866. (Pubitemid 28255657)
8. Sampson SR, Cooper DR. Specific protein kinase C isoforms as transducers and modulators of insulin signaling. Mol Genet Metab 2006; 89: 32-47. (Pubitemid 44205471)
9. Inagaki K, Chen L, Ikeno F, et al. Inhibition of delta-protein kinase C protects against reperfusion injury of the ischemic heart in vivo. Circulation 2003; 108: 2304-2307. (Pubitemid 37413533)
10. Budas GR, Churchill EN, Mochly-Rosen D. Cardioprotective mechanisms of PKC isozyme-selective activators and inhibitors in the treatment of ischemia-reperfusion injury. Pharmacol Res 2007; 55: 523-536. (Pubitemid 46962304)
11. Bright R, Mochly-Rosen D. The role of protein kinase C in cerebral ischemic and reperfusion injury. Stroke 2005; 36: 2781-2790.
12. Chou WH, Messing RO. Hypertensive encephalopathy and the blood-brain barrier: Is deltaPKC a gatekeeper? J Clin Invest 2008; 118: 17-20.
13. Sun MK, Alkon DL. Protein kinase C pharmacology: Perspectives on therapeutic potentials as antidementic and cognitive agents. Recent Pat CNS Drug Discov 2006; 1: 147-156.
14. 2+-sensitive isoforms in the failing human heart. Circulation 1999; 99: 384-391.
15. Teicher BA, Menon K, Alvarez E, Shih C, Faul MM. Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human breast cancer and ovarian cancer xenografts. Invest New Drugs 2002; 20: 241-251. (Pubitemid 34823752)
16. Isakov N, Altman A. Protein kinase C(theta) in T cell activation. Annu Rev Immunol 2002; 20: 761-794. (Pubitemid 34293439)
17. Teicher BA. Protein kinase C as a therapeutic target. Clin Cancer Res 2006; 12: 5336-5345.
18. Paz-Ares L, Douillard JY, Koralewski P, et al. Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2006; 24: 1428-1434. (Pubitemid 46622009)
19. 2+, phospholipids-dependent protein kinase associated with plasma membrane. Nature 1983; 301: 621-623.
20. Mochly-Rosen D, Henrich CJ, Cheever L, Khaner H, Simpson PC. A protein kinase C isozyme is translocated to cytoskeletal elements on activation. Cell Regul 1990; 1: 693-706.
21. Ron D, Chen CH, Caldwell J, Jamieson L, Orr E, Mochly-Rosen D. Cloning of an intracellular receptor for protein kinase C: A homolog of the beta subunit of G proteins. Proc Natl Acad Sci USA 1994; 91: 839-843. (Pubitemid 24048462)
22. Csukai M, Chen CH, De Matteis MA, Mochly-Rosen D. The coatomer protein beta'-COP, a selective binding protein (RACK) for protein kinase Cepsilon. J Biol Chem 1997; 272: 29200-29206. (Pubitemid 27498211)
23. Ron D, Luo J, Mochly-Rosen D. C2 region-derived peptides inhibit translocation and function of beta protein kinase C in vivo. J Biol Chem 1995; 270: 24180-24187.
24. Fong HK, Amatruda TT 3rd, Birren BW, Simon MI. Distinct forms of the beta subunit of GTP-binding regulatory proteins identified by molecular cloning. Proc Natl Acad Sci USA 1987; 84: 3792-3796.
25. Harrison-Lavoie KJ, Lewis VA, Hynes GM, Collison KS, Nutland E, Willison KR. A 102 kDa subunit of a Golgi-associated particle has homology to beta subunits of trimeric G proteins. EMBO J 1993; 12: 2847-2853. (Pubitemid 23218334)
26. Stenbeck G, Harter C, Brecht A, et al. beta'-COP, a novel subunit of coatomer. EMBO J 1993; 12: 2841-2845.
27. Birikh KR, Sklan EH, Shoham S, Soreq H. Interaction of "readthrough" acetylcholinesterase with RACK1 and PKCbeta II correlates with intensified fear-induced conflict behavior. Proc Natl Acad Sci USA 2003; 100: 283-288.
28. Schechtman D, Mochly-Rosen D. Adaptor proteins in protein kinase C-mediated signal transduction. Oncogene 2001; 20: 6339-6347. (Pubitemid 32977843)
29. Abeliovich A, Chen C, Goda Y, Silva AJ, Stevens CF, Tonegawa S. Modified hippocampal long-term potentiation in PKC gamma-mutant mice. Cell 1993; 75: 1253-1262. (Pubitemid 24021901)
30. Abeliovich A, Paylor R, Chen C, Kim JJ, Wehner JM, Tonegawa S. PKC gamma mutant mice exhibit mild deficits in spatial and contextual learning. Cell 1993; 75: 1263-1271. (Pubitemid 2029892)
31. Leitges M, Schmedt C, Guinamard R, et al. Immunodeficiency in protein kinase cbeta-deficient mice. Science 1996; 272: 728-731. (Pubitemid 26271522)
32. Su TT, Guo B, Kawakami Y, et al. PKC-beta controls I kappa B kinase lipid raft recruitment and activation in response to BCR signaling. Nat Immunol 2002; 3: 780-786. (Pubitemid 34884835)
33. Hodge CW, Mehmert KK, Kelley SP, et al. Supersensitivity to allosteric GABA(A) receptor modulators and alcohol in mice lacking PKCepsilon. Nat Neurosci 1999; 2: 997-1002.
34. Castrillo A, Pennington DJ, Otto F, Parker PJ, Owen MJ, Boscá L. Protein kinase C epsilon is required for macrophage activation and defense against bacterial infection. J Exp Med 2001; 194: 1231-1242. (Pubitemid 33055042)
35. Schmitz-Peiffer C, Laybutt DR, Burchfield JG, et al. Inhibition of PKCepsilon improves glucose-stimulated insulin secretion and reduces insulin clearance. Cell Metab 2007; 6: 320-328. (Pubitemid 47450184)
36. Sun Z, Arendt CW, Ellmeier W, et al. PKC-theta is required for TCR-induced NF-kappaB activation in mature but not immature T lymphocytes. Nature 2000; 404: 402-407. (Pubitemid 30164343)
37. Leitges M, Mayr M, Braun U, et al. Exacerbated vein graft arteriosclerosis in protein kinase Cdelta-null mice. J Clin Invest 2001; 108: 1505-1512. (Pubitemid 33091988)
38. Leitges M, Gimborn K, Elis W, et al. Protein kinase C-delta is a negative regulator of antigen-induced mast cell degranulation. Mol Cell Biol 2002; 22: 3970-3980. (Pubitemid 34556568)
39. Mecklenbräuker I, Saijo K, Zheng NY, Leitges M, Tarakhovsky A. Protein kinase C-delta controls self-antigen-induced B-cell tolerance. Nature 2002; 416: 860-865. (Pubitemid 34453743)
40. Miyamoto A, Nakayama K, Imaki H, et al. Increased proliferation of B cells and auto-immunity in mice lacking protein kinase C-delta. Nature 2002; 416: 865-869. (Pubitemid 34453744)
41. Leitges M, Sanz L, Martin P, et al. Targeted disruption of the zetaPKC gene results in the impairment of the NF-kappaB pathway. Mol Cell 2001; 8: 771-780. (Pubitemid 33030211)
42. Martin P, Duran A, Minguet S, et al. Role of zeta PKC in B-cell signaling and function. EMBO J 2002; 21: 4049-4057. (Pubitemid 34857437)
43. Soloff RS, Katayama C, Lin MY, Feramisco JR, Hedrick SM. Targeted deletion of protein kinase C lambda reveals a distribution of functions between the two atypical protein kinase C isoforms. J Immunol 2004; 173: 3250-3260. (Pubitemid 39142033)
44. Farese RV, Sajan MP, Yang H, et al. Muscle-specific knockout of PKC-lambda impairs glucose transport and induces metabolic and diabetic syndromes. J Clin Invest 2007; 117: 2289-22301.
45. Hashimoto N, Kido Y, Uchida T, et al. PKC lambda regulates glucose-induced insulin secretion through modulation of gene expression in pancreatic beta cells. J Clin Invest 2005; 115: 138-145. (Pubitemid 40385514)
46. Chida K, Hara T, Hirai T, et al. Disruption of protein kinase ceta results in impairment of wound healing and enhancement of tumor formation in mouse skin carcinogenesis. Cancer Res 2003; 63: 2404-2408. (Pubitemid 36605176)
47. Braz JC, Gregory K, Pathak A, et al. PKC-alpha regulates cardiac contractility and propensity toward heart failure. Nat Med 2004; 10: 248-254. (Pubitemid 38667614)
48. Leitges M, Plomann M, Standaert ML, et al. Knockout of PKC alpha enhances insulin signaling through PI3K. Mol Endocrinol 2002; 16: 847-858. (Pubitemid 34297752)
49. Ikeno, F., Inagaki, K., Mochly-Rosen, D., Rezaee, M.: WO2006080941 (2006).
50. Mochly-Rosen, D., Koyanagi, T., Inagaki, K., Ootani, A.: WO2008137118 (2008).
51. Ponting CP, Parker PJ. Extending the C2 domain family: C2s in PKCs delta, epsilon, eta, theta, phospholipases, GAPs, and perforin. Protein Sci 1996; 5: 162-166.
52. Disatnik MH, Hernandez-Sotomayor SM, Jones G, Carpenter G, Mochly-Rosen D. Phospholipase C-gamma 1 binding to intracellular receptors for activated protein kinase C. Proc Natl Acad Sci USA 1994; 91: 559-563. (Pubitemid 2042557)
53. Mochly-Rosen D, Miller KG, Scheller RH, Khaner H, Lopez J, Smith BL. P65 fragments, homologous to the C2 region of protein kinase C, bind to the intracellular receptors for protein kinase C. Biochemistry 1992; 31: 8120-8124.
54. Ron D, Luo J, Mochly-Rosen D. C2 region-derived peptides inhibit translocation and function of beta protein kinase C in vivo. J Biol Chem 1995; 270: 24180-24187.
55. Chen L, Hahn H, Wu G, et al. Opposing cardioprotective actions and parallel hypertrophic effects of delta PKC and epsilon PKC. Proc Natl Acad Sci USA 2001; 98: 11114-11119. (Pubitemid 32928691)
56. Bright R, Raval AP, Dembner JM, et al. Protein kinase C delta mediates cerebral reperfusion injury in vivo. J Neurosci 2004; 24: 6880-6888. (Pubitemid 39045444)
57. Braun MU, Mochly-Rosen D. Opposing effects of delta- and zeta-protein kinase C isozymes on cardiac fibroblast proliferation: Use of isozyme-selective inhibitors. J Mol Cell Cardiol 2003; 35: 895-903. (Pubitemid 36871014)
58. Tanaka M, Terry RD, Mokhtari GK, et al. Suppression of graft coronary artery disease by a brief treatment with a selective epsilonPKC activator and a deltaPKC inhibitor in murine cardiac allografts. Circulation 2004; 110(II): 194-199.
59. Brandman R, Disatnik MH, Churchill E, Mochly-Rosen D. Peptides derived from the C2 domain of protein kinase C epsilon (epsilon PKC) modulate epsilon PKC activity and identify potential protein-protein interaction surfaces. J Biol Chem 2007; 282: 4113-4123. (Pubitemid 47084489)
60. Johnson JA, Gray MO, Chen CH, Mochly-Rosen D. A protein kinase C translocation inhibitor as an isozyme-selective antagonist of cardiac function. J Biol Chem 1996; 271: 24962-24966. (Pubitemid 26333253)
61. Dorn GW 2nd, Souroujon MC, Liron T, et al. Sustained in vivo cardiac protection by a rationally designed peptide that causes epsilon protein kinase C translocation. Proc Natl Acad Sci USA 1999; 96: 12798-12803.
62. Sweitzer SM, Wong SM, Peters MC, Mochly-Rosen D, Yeomans DC, Kendig JJ. Protein kinase C epsilon and gamma: involvement in formalin-induced nociception in neonatal rats. J Pharmacol Exp Ther 2004; 309: 616-625. (Pubitemid 38542615)
63. Shirai Y, Adachi N, Saito N. Protein kinase Cepsilon: function in neurons. FEBS J 2008; 275: 3988-3994.
64. Davis JB, Gray J, Gunthorpe MJ, et al. Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia. Nature 2000; 405: 183-187. (Pubitemid 30313536)
65. Premkumar LS, Ahern GP. Induction of vanilloid receptor channel activity by protein kinase C. Nature 2000; 408: 985-990. (Pubitemid 32101646)
66. Tominaga M, Wada M, Masu M. Potentiation of capsaicin receptor activity by metabotropic ATP receptors as a possible mechanism for ATP-evoked pain and hyperalgesia. Proc Natl Acad Sci USA 2001; 98: 6951-6956. (Pubitemid 32538323)
67. Mandadi S, Tominaga T, Numazaki M, et al. Increased sensitivity of desensitized TRPV1 by PMA occurs through PKCepsilonmediated phosphorylation at S800. Pain 2006; 123: 106-116. (Pubitemid 43816763)
68. Sweitzer SM, Wong SM, Tjolsen A, et al. Exaggerated nociceptive responses on morphine withdrawal: Roles of protein kinase C epsilon and gamma. Pain 2004; 110: 281-289. (Pubitemid 38953293)
69. Shafrir, E., Ziv, E., Reuveni, H., Niv, M.: WO2007000770 (2007).
70. Ben-Sasson, S.: US6174993 (1997).
71. Mack E, Ziv E, Reuveni H, et al. Prevention of insulin resistance and beta-cell loss by abrogating PKCepsilon-induced serine phosphorylation of muscle IRS-1 in Psammomys obesus. Diabetes Metab Res Rev 2008; 24: 577-584.
72. Niv MY, Rubin H, Cohen J, et al. Sequence-based design of kinase inhibitors applicable for therapeutics and target identification. J Biol Chem 2004; 279: 1242-1255. (Pubitemid 38082648)
73. Begley R, Liron T, Baryza J, Mochly-Rosen D. Biodistribution of intracellularly acting peptides conjugated reversibly to Tat. Biochem Biophys Res Commun 2004; 318(4): 949-954. (Pubitemid 38625866)
74. Chen CH, Budas GR, Churchill EN, Disatnik MH, Hurley TD, Mochly-Rosen D. Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart. Science 2008; 321: 1493-1495.
75. Mochly-Rosen, D., Chen, C.-H.:WO2005057213 (2005).